Article view: 166

Article download: 62

Indian Journal of Clinical and Experimental Ophthalmology


Study of efficacy of intravitreal triamcinolone acetonide (IVTA) for the treatment of refractory diabetic macular edema (DME) in type 2 diabetes mellitus patients


Full Text PDF Share on Facebook Share on Twitter


Research Article

Author Details : Pankaj Soni*, Ashutosh Kumar Singh, Suroma Joysmine Marndi

Volume : 5, Issue : 3, Year : 2019

Article Page : 401-406


Suggest article by email


Abstract

Aim: To study the efficacy of intravitreal triamcinolone acetonide (IVTA) for the treatment of refractory diabetic macular edema (DME) in type 2 diabetes mellitus patients.
Materials and Methods: A prospective, interventional, non-comparative case series. There were 13 eyes of 13 patients with refractory DME. An intravitreal injection of triamcinolone acetonide at the dose of 4 mg in 0.1 ml was administered. Best corrected visual acuity was measured at each examination. The amount of hard exudates deposition in the macula was subjectively evaluated using colour fundus photographs. Central macular thickness (CMT) was measured, on OCT.
Results: 13 patients completed 6 months or more of follow up and were included in the study. Sex distribution in the study was 12 (92.40%) males and 1 female (7.60%). There was significant improvement in the visual acuity, 2.42 ± 1 (mean ± SD) (p<0>
Conclusions: Intravitreal injection of 4 mg of triamcinolone acetonide may be beneficial for improving visual acuity in type 2 diabetes patients which have refractory diabetic macular edema.

Keywords: Diabetic Macular Edema (DME), Intra Vitreal Triamcinolone Acetonide (IVTA).

Doi : 10.18231/j.ijceo.2019.097

How to cite : Soni P , Singh A K, Marndi S J, Study of efficacy of intravitreal triamcinolone acetonide (IVTA) for the treatment of refractory diabetic macular edema (DME) in type 2 diabetes mellitus patients. Indian J Clin Exp Ophthalmol 2019;5(3):401-406

Copyright © 2019 by author(s) and Indian J Clin Exp Ophthalmol. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (creativecommons.org)